TABLE 5.

Trial sponsor for each phase of Alzheimer's disease drug development (ClinicalTrials.gov accessed February 27, 2020)

	N of trials (%)
Sponsor	Phase 1	Phase 2	Phase 3	Total
Biopharma industry	12 (44%)	28 (38%)	22 (61%)	62 (46%)
Academic medical centers	12 (44%)	33 (45%)	8 (22%)	53 (39%)
NIH	1 (4%)	0	0	1 (1%)
Other federal agencies (eg, VA)	0	3 (4%)	1 (3%)	4 (3%)
Industry and NIH	1 (4%)	3 (4%)	1 (3%)	5 (4%)
Industry and consortium/foundation	1 (4%)	3 (4%)	2 (6%)	6 (4%)
NIH and consortium/foundation	0	1 (1%)	0	1 (1%)
NIH and consortium/foundation and industry	0	2 (3%)	1 (3%)	3 (2%)
NIH and consortium/foundation and industry and academic	0	0	1 (3%)	1 (3%)

Abbreviations: NIH, National Institutes of Health; VA, veterans affairs.